Stock Price Movement and Market Context
On 12 Jan 2026, Syncom Formulations’ stock price slipped to Rs.12.78, its lowest level in the past 52 weeks. This decline comes after three consecutive days of losses, during which the stock has fallen by 6.8%. Despite this, the stock marginally outperformed its sector today by 0.27%, though it remains well below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward momentum.
In contrast, the broader market has shown resilience. The Sensex, after an initial negative opening down by 140.93 points, recovered to close 0.09% higher at 83,647.99, just 3% shy of its 52-week high of 86,159.02. Mega-cap stocks have led this recovery, while the Sensex trades below its 50-day moving average but with the 50DMA still above the 200DMA, signalling a cautiously positive medium-term trend.
Performance Relative to Benchmarks
Over the past year, Syncom Formulations has underperformed significantly. The stock has generated a negative return of 28.05%, in stark contrast to the Sensex’s positive 8.10% gain and the BSE500’s 7.18% return. This divergence highlights the stock’s relative weakness within the pharmaceuticals and biotechnology sector, as well as the broader market.
Financial Performance and Growth Trends
Syncom Formulations’ long-term financial metrics reveal subdued growth. Over the last five years, net sales have declined at an annualised rate of 63.63%, while operating profit has contracted by 52.27%. These figures underscore the company’s struggles to expand its revenue base and profitability over an extended period.
However, recent half-yearly results show some positive developments. The company reported net sales of Rs.238.62 crores in the latest six months, reflecting a growth of 25.87%. Operating profit increased by 8.29%, and profit after tax (PAT) surged by 72.46% to Rs.32.32 crores. Return on capital employed (ROCE) for the half-year stood at a robust 22.06%, while return on equity (ROE) was a fair 16.6%. These figures suggest an improvement in operational efficiency and profitability in the short term.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Valuation and Market Perception
Despite recent profit growth, Syncom Formulations trades at a premium relative to its peers’ historical valuations. The stock’s price-to-book value stands at 3.3, which is elevated given the company’s recent performance. The PEG ratio, which compares price-to-earnings growth, is low at 0.2, reflecting the disconnect between the stock price and earnings growth.
Domestic mutual funds hold no stake in the company, a notable point given their capacity for detailed research and due diligence. This absence may indicate a cautious stance towards the stock’s valuation or business prospects at current levels.
Balance Sheet and Financial Health
Syncom Formulations maintains a conservative capital structure, with an average debt-to-equity ratio of just 0.05 times. This low leverage reduces financial risk and provides flexibility for future capital allocation. The company’s market capitalisation grade is rated 3, reflecting its moderate size within the pharmaceuticals and biotechnology sector.
Stock Rating and Momentum
The company’s Mojo Score currently stands at 46.0, with a Mojo Grade of Sell, downgraded from Hold as of 1 Aug 2025. This rating reflects the stock’s recent underperformance and the challenges it faces in delivering sustained growth. The day’s price change was a decline of 0.76%, continuing the downward trend.
Syncom Formulations (India) Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Metrics
To summarise, Syncom Formulations has experienced a challenging year with a 28.05% decline in share price, despite recent improvements in profitability and sales growth. The stock’s current trading level of Rs.12.78 represents a significant drop from its 52-week high of Rs.23.46. While the company’s financial health remains stable with low debt and improving returns, its valuation remains elevated relative to peers, and it continues to lag behind broader market indices.
The stock’s downgrade to a Sell grade by MarketsMOJO reflects these factors, alongside the absence of domestic mutual fund participation and the sustained downward price momentum. Investors analysing the stock will note the contrast between recent positive earnings trends and the longer-term sales decline, which continues to weigh on market sentiment.
Unlock special upgrade rates for a limited period. Start Saving Now →
